SEARCH

SEARCH BY CITATION

References

  • 1
    Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461472.
  • 2
    Bousquet J, Van Cauvenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:147334.
  • 3
    Malling HJ, Weeke B. EAACI Immunotherapy position papers. Allergy 1993;48(Suppl. 14):935.
  • 4
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brian F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468475.
  • 5
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991;302:265269.
  • 6
    Bousquet J, Lockey RF, Malling H-J (Eds). WHO Position Paper. Allergen Immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl 44):142.
  • 7
    Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus product. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797802.
  • 8
    Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized products. Allergy 1993;48:450453.
  • 9
    Wells JH. Systemic reactions to immunotherapy: comparisons between two large allergy practices. J Allergy Clin Immunol 1996;97:10301032.
  • 10
    Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. EAACI Interest Group on Insect Venom Hypersensitivity Group. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:14591470.
  • 11
    Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial in insect hypersensitivity. New Engl J Med 1978;299:157161.
  • 12
    Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigné R. Immunotherapy in bee sting hypersensitivity: bee venom versus whole body product. Allergy 1979;34:369378.
  • 13
    Brown S, Wiese M, Blackman K, Heddle R. Ant venom immunotherapy: a double blind, placebo controlled cross-over trial. Lancet 2003;361:10011006.
  • 14
    Rueff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in hymenoptera venom allergy. Allergy 1996;51:216225.
  • 15
    Müller U, Helbling A, Berchtold E. Immunotherapy with honey bee venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529535.
  • 16
    Mosbech H, Müller U. Side effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000;55:10051010.
  • 17
    Müller U, Mosbech H. EAACI Position Paper: immunotherapy with Hymenoptera venoms. Allergy 1993;48:3646.
  • 18
    Müller U, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005;115:606610.
  • 19
    Des Roches A, Paradis L, Ménardo J-L, Bouges S, Daurès J-P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus product. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450453.
  • 20
    Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Purcinelli P, Parmiciani S et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or nor. A retrospective study. Clin Exp Allergy 2001;31:12951302.
  • 21
    Pajno GB, Barberio G, De Luca FR, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:13921397.
  • 22
    Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251256.
  • 23
    Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Current Opinion in Immunology 2002;14:718727.
  • 24
    Adkinson NF Jr., Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324331.
  • 25
    Malling H-J. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323332.
  • 26
    Javeed N, Javeed H, Javeed S, Moussa G, Wong P, Rezai F. Refractory anaphylactoid shock potentiated by β-blockers. Cathet Cardiovasc Diagn 1996;39:383384.
  • 27
    Wantke F, Demmer CM, Götz M, Jarisch R. Inhibition of diamine oxidase is a risk in specific immunotherapy. Allergy 1993;48:552.
  • 28
    Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus product. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797802.
  • 29
    Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96:971979.
  • 30
    Nielsen L, Johnsen ER, Mosbech H, Poulse LK, Malling H-J. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996;97:12071213.
  • 31
    Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001;107:8186.
  • 32
    Delacourt C, Benoist MR, Wearnessyckle S, Rufin P, Brouard JJ, De Blic J et al. Relationship between bronchial responsiveness and clinical evolution in infants who wheeze: a four-year prospective study. Am J Respir Crit Care Med 2001;164:13821386.
  • 33
    Van Den Toorn LM, Overbeek SE, Prins JB, Hoogsteden HC, De Jongste JC. Asthma remission: does it exist? Curr Opin Pulm Med 2003;9:520.